Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sperm lysozyme-like protein 1 (SLLP1) is a non-bacteriolytic c-type lysozyme-like protein specifically localized in the acrosome of human spermatozoa. Unlike traditional lysozymes, SLLP1 lacks catalytic activity due to mutations in key active site residues, but it plays a critical role in fertilization by mediating the interaction between the sperm and the oocyte plasma membrane. It specifically binds to the oocyte surface receptor SASB1, facilitating sperm-egg recognition and adhesion. Beyond its role in reproduction, SLLP1 is classified as a cancer/testis antigen because it is ectopically expressed in various malignancies, including lung and breast cancers, while being restricted to the testis in healthy tissues. This restricted expression pattern and its essential role in fertilization make SLLP1 a promising target for the development of non-hormonal contraceptives and targeted cancer immunotherapies.
Potential contraceptive vaccines or small molecule inhibitors could target SLLP1 to block sperm-egg binding and prevent fertilization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sperm lysozyme-like protein 1 (SLLP1).